Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Ascending Multiple Oral Dose, Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia.

NCT03370640 is registered in ClinicalTrials.gov with Sumitomo Pharma Co., Ltd. as lead sponsor.

NCT NCT03370640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03370640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Ascending Multiple Oral Dose, Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia.
Lead sponsor
Sumitomo Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2017
Completion date
September 20, 2018
Enrollment
24 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia